Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lexaria Bioscience in a research report on Wednesday. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Lexaria Bioscience presently has an average rating of “Hold” and a consensus target price of $4.00.
Check Out Our Latest Report on Lexaria Bioscience
Lexaria Bioscience Trading Down 2.2%
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Lexaria Bioscience stock. Virtu Financial LLC acquired a new position in shares of Lexaria Bioscience Corp. (NASDAQ:LEXX – Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 29,360 shares of the company’s stock, valued at approximately $28,000. Virtu Financial LLC owned approximately 0.13% of Lexaria Bioscience as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 13.06% of the company’s stock.
About Lexaria Bioscience
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.
Read More
- Five stocks we like better than Lexaria Bioscience
- Investing In Preferred Stock vs. Common Stock
- Power On: Applied Digital’s First AI Data Center Goes Live
- How to Use Stock Screeners to Find Stocks
- Alphabet: The AI Leader Best Positioned to Dominate 2026
- Where Do I Find 52-Week Highs and Lows?
- 2 Reasons to Load Up on Fiserv, 1 to Stay Away
Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
